News
NSPR
2.282
+1.40%
0.032
InspireMD to Present Key Trial Results at LINC 2024
TipRanks · 2d ago
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
An abstract of the one-year outcomes from the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis will be presented at the Leipzig Interventional Course in 2024. InspireMD, Inc. Is developer of the Cguard™ Embolic Prevention Stent system for the prevention of stroke.
Barchart · 2d ago
Weekly Report: what happened at NSPR last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at NSPR last week (0311-0315)?
Weekly Report · 03/18 10:31
Weekly Report: what happened at NSPR last week (0304-0308)?
Weekly Report · 03/11 10:29
NSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023
InspireMD reported earnings per share of -16 cents. The company reported revenue of $1.76 million. This was 8.04% better than the analyst estimate for revenue of -20 cents. InspireMD also reported better than expected quarterly results for the quarter.
Investorplace · 03/06 17:53
Earnings Scheduled For March 6, 2024
Foot Locker is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion. JD.com is expected to report earnings for its fourth quarter. CTS is estimated to report its quarterly earnings before the bell. Other companies reporting before the Bell include Campbell Soup, Super Group and Abercrombie & Fitch.
Benzinga · 03/06 10:00
Preview: InspireMD's Earnings
InspireMD is set to give its latest quarterly earnings report on Wednesday, 2024-03-06. Analysts estimate the company will report an earnings per share of $-0.19. Last quarter the company missed EPS by $0.00. Shares of InspireMD were trading at $2.57 as of March 04.
Benzinga · 03/05 19:02
Weekly Report: what happened at NSPR last week (0226-0301)?
Weekly Report · 03/04 10:32
Weekly Report: what happened at NSPR last week (0219-0223)?
Weekly Report · 02/26 10:40
Weekly Report: what happened at NSPR last week (0212-0216)?
Weekly Report · 02/19 10:41
Weekly Report: what happened at NSPR last week (0205-0209)?
Weekly Report · 02/12 10:34
Weekly Report: what happened at NSPR last week (0129-0202)?
Weekly Report · 02/05 10:39
InspireMD Secures CE Mark Recertification Under New EU Standards
TipRanks · 02/01 09:10
InspireMD Announces CE Mark Recertification Under MDR
TipRanks · 02/01 09:10
Weekly Report: what happened at NSPR last week (0122-0126)?
Weekly Report · 01/29 10:32
Weekly Report: what happened at NSPR last week (0115-0119)?
Weekly Report · 01/22 10:35
Weekly Report: what happened at NSPR last week (0108-0112)?
Weekly Report · 01/15 10:33
Weekly Report: what happened at NSPR last week (0101-0105)?
Weekly Report · 01/08 10:35
Weekly Report: what happened at NSPR last week (1225-1229)?
Weekly Report · 01/01 10:31
More
Webull provides a variety of real-time NSPR stock news. You can receive the latest news about Inspiremd through multiple platforms. This information may help you make smarter investment decisions.
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.